This renewal application seeks funding to continue the highly successful Cancer Therapeutics Training (CT2) Program at the Moores Comprehensive Cancer Center at the University of California, San Diego. The mission of the CT2 program is to train the PhD and physician-scientists who will become the next generation of leaders in the field of cancer therapeutics and diagnostics in each of the major steps required for successful translation of laboratory-based discoveries into safe and effective therapeutic agents and diagnostic modalities. The CT2 training is designed to position trainees to play key leadership roles in the field of cancer developmental therapeutics and diagnostics. The 22 faculty of the CT2 Program are all Members of the Cancer Center and are based in 10 departments in the School of Medicine, the Scripps Oceanographic Institute or the general campus. Each faculty mentor is an accomplished investigator and educator with a history of training superb post-doctoral fellows. Each has substantial peer-reviewed cancer or cancer-related research funding. All of the participating faculty are conducting translational research and have been selected because of their interest in new cancer therapeutics. This program is extensively integrated into the other cancer related activities of the Cancer Center and of UCSD. The goal is to recruit and retain 8 MD and PhD scientists in this two-year program that will position them for careers in the development of new cancer drugs or the diagnostics needed to guide the use of these drugs. The training program has 3 components: 1) the completion of formal didactic teaching sessions that cover tools essential to the drug development process;2) the conduct of a drug or diagnostic development research project under the direction of a faculty mentor;and, 3) required participation in the annual meeting of the American Association for Cancer Research or an equivalent national drug development meeting. Trainees are also expected to participate in Cancer Center and Departmental seminars, research rounds and journal clubs to expand the breadth of their understanding of cancer research, and prepare formal project plans and practice or real grant applications for review by the Executive Committee. Methods are in place to ensure that all trainees are properly instructed in the principles of responsible conduct of research and scientific integrity. Trainees are recruited nationwide and special efforts are made recruit and retain exceptional minority, women and disadvantaged candidates. During its first 4 years of operation the CT2 Program has drawn trainees from major research universities across the country as well as from the Gradate Biomedical Sciences, Hematology/Oncology, Surgery and Radiology fellowship programs UCSD. This Program has been so successful that the Cancer Center has established a parallel program of additional fellowships in cancer therapeutics funded by donations.
This application seeks funding to continue a training program in developmental therapeutics focused on cancer drugs at the Moores Cancer Center at the University of California, San Diego. Our vision is that cancer can be controlled with novel therapeutics directed at molecular targets critical for tumor cell survival when combined with biomarkers that allow individualization of treatment. The mission of the program is to provide training to post-doctoral PhD and physician-scientists in each of the major steps in the development of a novel cancer therapeutics so as to position these individuals to play leading roles in translating laboratory-based discoveries into safe and effective therapeutic agents.
|Lwin, Thinzar M; Hoffman, Robert M; Bouvet, Michael (2018) Advantages of patient-derived orthotopic mouse models and genetic reporters for developing fluorescence-guided surgery. J Surg Oncol 118:253-264|
|Insel, Paul A; Sriram, Krishna; Wiley, Shu Z et al. (2018) GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets. Front Pharmacol 9:431|
|Wiley, Shu Z; Sriram, Krishna; Liang, Wenjing et al. (2018) GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J 32:1170-1183|
|Lwin, Thinzar M; Murakami, Takashi; Miyake, Kentaro et al. (2018) Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore. Ann Surg Oncol 25:1079-1085|
|Lwin, Thinzar M; Hoffman, Robert M; Bouvet, Michael (2017) Regarding the applications of fusion-fluorescence imaging using indocyanine green in laparoscopic hepatectomy. Transl Gastroenterol Hepatol 2:70|
|Schutt, Carolyn; Ibsen, Stuart; Zahavy, Eran et al. (2017) Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin. Pharm Res 34:2025-2035|
|Yau, Edwin H; Kummetha, Indrasena Reddy; Lichinchi, Gianluigi et al. (2017) Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers. Cancer Res 77:6330-6339|
|Murakami, Takashi; Kiyuna, Tasuku; Kawaguchi, Kei et al. (2017) The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. Cell Cycle 16:1046-1052|
|Eckert, Mark A; Santiago-Medina, Miguel; Lwin, Thinzar M et al. (2017) ADAM12 induction by Twist1 promotes tumor invasion and metastasis via regulation of invadopodia and focal adhesions. J Cell Sci 130:2036-2048|
|Turner, Kristen M; Deshpande, Viraj; Beyter, Doruk et al. (2017) Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543:122-125|
Showing the most recent 10 out of 154 publications